MIT Researchers Develop Implantable Device Offering Long-Term Diabetes Control Without Injections

In a major advance for type 1 diabetes management, researchers at the Massachusetts Institute of Technology (MIT) have engineered a groundbreaking implantable device that could eliminate the need for daily insulin injections and lifelong immune-suppressing drugs. The device, tested in rodents, contains insulin-producing islet cells encapsulated within a protective casing that shields them from immune rejection while providing a continuous oxygen supply. For at least 90 days—three times longer than previous iterations—the cells remained viable, producing sufficient insulin to maintain healthy blood sugar levels in animals without external intervention. This innovation, published in the journal Device, represents a potential paradigm shift in diabetes care, offering a sustainable, long-term solution where current treatments fall short.

How the Implant Works: A Breakthrough in Diabetes Device Technology

The MIT team’s device addresses two critical challenges in islet cell transplantation: immune rejection and oxygen deprivation. Traditional islet transplants, sourced from cadaveric donors or stem cells, require patients to take immunosuppressive drugs indefinitely to prevent their immune systems from attacking the foreign cells. These drugs, while effective, carry severe side effects, including increased infection risk and organ damage. The MIT device circumvents this issue by encapsulating the islet cells in a semi-permeable membrane that physically blocks immune cells while allowing insulin and glucose to pass freely.

The Oxygen Generator: Keeping Cells Alive Without External Systems

A second innovation is the implant’s built-in oxygen generator, which solves a long-standing problem in cell encapsulation: oxygen deprivation. Cells need oxygen to survive, but implanted devices often suffer from hypoxia as the body’s natural supply is insufficient. The MIT device uses a proton-exchange membrane to split water vapor—abundant in bodily tissues—into hydrogen and oxygen. The hydrogen diffuses harmlessly away, while the oxygen is stored in a reservoir and delivered to the islet cells through a thin, oxygen-permeable membrane. In earlier prototypes, this system only sustained cells for about a month. However, the researchers enhanced its durability by improving waterproofing, reducing cracking, and optimizing the wireless power transfer system that energizes the oxygen generator.

‘A month is a good timeframe in that it shows basic proof-of-concept,’ said Siddharth Krishnan, a former MIT research scientist now an assistant professor at Stanford University and lead author of the study. ‘But from a translational standpoint, it’s important to show that you can go quite a bit longer than that.’ By increasing the device’s resilience and power efficiency, the team extended its functional lifespan to 90 days in rodent models—a duration they believe is sufficient to demonstrate clinical relevance for human applications.

From Cadaveric Cells to Stem Cells: Expanding the Supply of Insulin-Producing Cells

The MIT device has been tested with two primary sources of insulin-producing islet cells: cadaveric human islets and stem cell-derived islets. Cadaveric islets, though functional, are in limited supply and carry the risk of immune rejection even with encapsulation. Stem cell-derived islets, generated from induced pluripotent stem cells (iPSCs), offer a potentially unlimited and customizable supply. Unlike cadaveric cells, iPSC-derived islets can be produced in large quantities and tailored to individual patients, reducing the risk of immune response.

In the study, the researchers implanted devices containing both cadaveric and stem cell-derived islets into rodents. While neither fully reversed diabetes, both significantly controlled blood sugar levels over the 90-day period. ‘We’re hoping that in the future, if we can give the cells a little bit longer to fully mature, that they’ll secrete even more insulin to better regulate diabetes in the animals,’ said Matthew Bochenek, a former MIT postdoc and co-lead author of the study. The team is now exploring whether prolonging the cell maturation process could achieve full diabetes reversal in preclinical models.

Why This Matters: The Limitations of Current Diabetes Treatments

Type 1 diabetes, an autoimmune condition in which the pancreas produces little to no insulin, affects an estimated 1.6 million Americans, with over 64,000 new diagnoses each year, according to the Centers for Disease Control and Prevention (CDC). The standard treatment involves meticulous blood sugar monitoring and multiple daily insulin injections or the use of an insulin pump. While life-saving, this regimen is burdensome, requiring constant vigilance to avoid dangerous fluctuations in blood sugar that can lead to complications such as nerve damage, kidney failure, and cardiovascular disease.

The Burden of Insulin Dependence and Immune Suppression

For patients with severe cases, islet cell transplantation offers a more stable alternative. However, the procedure requires lifelong immunosuppression to prevent rejection, which can lead to serious health complications. ‘Islet cell therapy can be a transformative treatment for patients,’ explained Daniel Anderson, a professor of chemical engineering at MIT and senior author of the study. ‘However, current methods also require immune suppression, which for some people can be really debilitating.’ Anderson’s team aims to eliminate this trade-off by creating a device that protects the cells from the immune system without drugs.

The financial burden of diabetes is also staggering. The American Diabetes Association estimates the total cost of diagnosed diabetes in the U.S. exceeded $412 billion in 2022, with insulin alone accounting for tens of billions in direct medical expenses. A long-term, injectable-free solution could reduce both the economic and emotional toll on patients and healthcare systems.

The Science Behind the Innovation: A Closer Look at the Device

The MIT device is a small, flat implant designed to be placed just under the skin, similar to a glucose monitor or pacemaker. It measures approximately 1 centimeter in diameter and is powered wirelessly by an external antenna placed on the skin. The antenna transfers energy to the implant, which then powers the oxygen-generating system. The device’s circuitry has been optimized to maximize power delivery, ensuring the oxygen generator operates efficiently throughout the implant’s lifespan.

The encapsulation membrane is made from a biocompatible material that allows glucose and insulin to pass freely while blocking larger immune cells. This selective permeability is crucial, as it enables the islet cells to respond dynamically to the body’s blood sugar levels by releasing insulin as needed. The researchers used a hydrogel-based material for the membrane, which they engineered to be both durable and flexible, reducing the risk of cracking or failure over time.

Broader Implications: Beyond Diabetes Treatment

While the immediate focus is on diabetes, the MIT team envisions wider applications for their device platform. ‘We think that these technologies could provide a long-term way to treat human disease by making drugs in the body instead of outside of the body,’ said Anderson. The same encapsulation and oxygen-delivery system could be adapted to deliver other protein-based therapies, such as antibodies for autoimmune diseases, enzymes for metabolic disorders, or clotting factors for hemophilia. This ‘living drug factory’ concept could eliminate the need for frequent infusions or injections, improving patient compliance and outcomes.

The Road to Human Trials: Challenges and Next Steps

Before the device can be tested in humans, the MIT researchers must address several key challenges. First, they aim to extend the device’s lifespan to at least two years in preclinical models, demonstrating durability comparable to long-term medical implants. They are also exploring ways to scale up the manufacturing process to produce devices that meet regulatory standards for clinical use.

Another hurdle is ensuring the device’s safety and efficacy in larger animals, such as pigs, whose physiology more closely resembles humans. ‘Long-term survival of the islets is an important goal,’ Anderson noted. ‘The cells, if they’re in the right environment, seem to be able to survive for a long time. We are excited by the duration we’ve already achieved, and we will be working to extend their function as long as possible.’

The researchers are collaborating with the Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science at MIT, leveraging their expertise in biomaterials and medical device development. They have also filed patents for the technology and are in discussions with potential industry partners to accelerate the translation from lab to clinic.

Expert Reactions: What the Scientific Community is Saying

The study has generated significant interest within the diabetes research community. Dr. Gordon Weir, a diabetes researcher at the Joslin Diabetes Center and Harvard Medical School, who was not involved in the study, called the work ‘a substantial step forward.’ ‘The combination of encapsulation and on-board oxygen generation addresses two of the biggest obstacles in islet transplantation,’ Weir said. ‘If these devices can achieve similar results in humans, it could revolutionize how we treat type 1 diabetes.’

Other experts caution that translating animal data to human success is not guaranteed. Dr. Alice Tomei, an associate professor at the Diabetes Research Institute at the University of Miami, noted that the human body presents additional complexities, such as variations in oxygen availability and immune responses. ‘The device’s performance in humans will depend on a multitude of factors, including the site of implantation and the patient’s overall health,’ she said. ‘However, the progress is encouraging and warrants further investigation.’

Key Takeaways

• MIT researchers developed an implantable device containing insulin-producing islet cells that can regulate blood sugar for at least 90 days in animal models without daily injections or immune-suppressing drugs.
• The device uses a built-in oxygen generator to prevent cell death from oxygen deprivation, a common issue in encapsulated cell therapies.
• Both cadaveric and stem cell-derived islet cells were successfully used in the device, with stem cells offering a potentially unlimited supply.
• The technology could extend beyond diabetes to deliver other protein-based therapies, such as antibodies or clotting factors.
• Human trials are the next step, with researchers aiming to extend the device’s lifespan to two years or more.

Frequently Asked Questions